$SGEN News

Last published 8mo ago

8mo agoCMPX MRK SGEN PFE+8Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsightPR NewswireThe biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing...
1y agoSGENApproval of Adcetris, Bla #125388FDA Approved DrugsApproval Date: 02/11/2025; Drug Name: Adcetris, Bla #125388; Active Ingredients: BRENTUXIMAB VEDOTIN; Company: Seattle Genetics; Submission Status: Approval; Application Number: 125388
2y agoAPRE OMTH NRG MEDX+11Alltrna Announces Updates to Its Board of DirectorsPR NewswireAlltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and...
2y agoPFE SGENPfizer Completes Acquisition of SeagenBusiness WireFurther establishes Pfizer as a leading oncology company poised to accelerate the next generation of breakthrough treatments for people with cancer To address U.S. Federal Trade Commission concerns, Pfizer has
2y agoPFE SGEN BNTX MRNA+3Pfizer shares fall as 2024 revenue and profit forecast disappointsCNBCAfter raking in billions from Covid products, Pfizer has struggled to navigate a world beyond the pandemic and reassure investors about its growth potential.
2y agoNDAQ PFE SGEN TTWO+1Update: Annual Changes to the Nasdaq-100® IndexGlobeNewswireNEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced an update to the annual reconstitution of the Nasdaq-100 Index® (NASDAQ:NDX). Per the announcement by Pfizer Inc. (NYSE:PFE), the
2y agoPFE SGENPfizer Receives All Required Regulatory Approvals to Complete the Acquisition of SeagenBusiness WireExpects to close Seagen acquisition on December 14, 2023 Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution Pfizer to host analyst and investor call at
2y agoSGENADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin LymphomaBusiness Wire– 88% of patients with advanced stage classical Hodgkin Lymphoma in trial remained progression free at 24 months – – Investigational regimen that eliminates two commonly used chemotherapy agents, vinblastine and
2y agoSGENTUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast CancerBusiness Wire-- Results of Phase 3 HER2CLIMB-02 trial featured in an oral presentation and official press program at the 2023 San Antonio Breast Cancer Symposium -- Seagen Inc. (NASDAQ:SGEN) today announced data from the Phase 3
2y agoSGENFDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder CancerPR NewswireAstellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") and Seagen Inc. (Nasdaq: SGEN) today announced that on November 30,...
2y agoSGENFDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder CancerBusiness Wire– Results of pivotal confirmatory trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall survival and progression-free survival vs standard platinum containing chemotherapy– –
2y agoIMGN ABBV XBI .NBI+6Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billionCNBCOther biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the news of AbbVie's buyout of ImmunoGen.
3y agoSGENSeagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual MeetingBusiness Wire– Initial Phase 2 data presented for ADCETRIS in combination with immunotherapy pembrolizumab in metastatic non-small cell lung cancer and metastatic cutaneous melanoma – – Preclinical data presented for novel
3y agoSGENNew Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug ConjugateBusiness Wire– Updated Phase 2 data for ADCETRIS in combination with nivolumab in early and advanced stage classical Hodgkin lymphoma to be presented in oral session – – First preclinical data for investigational antibody-drug
3y agoSGENSeagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline ProgressBusiness Wire-Record Net Product Sales of $571 Million in 3Q23, a 33% Increase Over 3Q22, Primarily Driven by PADCEV® First-Line Launch- -PADCEV with Keytruda® Potentially Practice Changing for First-Line Metastatic
3y agoPFE MRNA BMY LLY+2Pfizer swings to quarterly loss due to Paxlovid, Covid vaccine write-offsCNBCThe results come two weeks after Pfizer slashed its full-year adjusted earnings and revenue guidance and launched a sweeping $3.5 billion cost-cutting plan.
3y agoSGEN TYO:4503Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder CancerBusiness Wire– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy – – Enfortumab vedotin plus pembrolizumab improved median overall survival by more than 15
3y agoSGENGroundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder CancerPR NewswireAstellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") and Seagen Inc. (Nasdaq: SGEN) today announced results from the Phase 3 ...
3y agoGMAB SGENTIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 TrialBusiness WireTIVDAK demonstrated superior overall survival, progression-free survival and objective response rate compared to chemotherapy in late-breaking results presented at ESMO 2023 congress Results from innovaTV 301 intended
3y agoBNTX ONCY SGEN MYGN+1Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment ResearchPR NewswireUSA News Group - According to the American Cancer Society in its Cancer Facts & Figures 2023 report, the five-year survival rate for pancreatic...
3y agoSGENSeagen to Highlight Overall Survival Data for PADCEV® and TIVDAK® during Presidential Symposium at ESMO Congress 2023Business Wire– Late-breaking results from global Phase 3 confirmatory studies of PADCEV (EV-302) in locally advanced or metastatic bladder cancer and TIVDAK (innovaTV 301) in recurrent or metastatic cervical cancer to be included in
3y agoPFE SGENPfizer slashes full-year earnings and revenue guidance as Covid treatment, vaccine sales slumpCNBCPfizer said it anticipates sales of its Covid treatment Paxlovid and its vaccine will be $9 billion less than it had expected.
3y agoSGENSeagen to Report Third Quarter 2023 Financial Results on November 1, 2023Business WireSeagen Inc. (NASDAQ:SGEN) announced today that it will report third quarter 2023 financial results on Wednesday, November 1, 2023. Given the previously announced agreement to be acquired by Pfizer Inc., Seagen will
3y agoCRNX GNLX ONCY PFE+1Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future TreatmentPR NewswireFN Media Group Presents USA News Group News Commentary VANCOUVER, British Columbia, Oct. 11, 2023 /PRNewswire/ -- USA News Group - Researchers are becoming increasingly concerned with the rates of cancer on the rise
3y agoF SQSP SCHL SGEN+5Stocks making the biggest moves midday: Ford, Scholastic, Squarespace, Deere and moreCNBCThese are the stocks posting the largest moves in midday trading.
3y agoPDD CHTR AZN-GB W+5Stocks making the biggest moves premarket: AstraZeneca, Wayfair, Alibaba and moreCNBCThese are the stocks posting the largest moves before the bell.
3y agoSGEN TYO:4503PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 TrialBusiness Wire– Trial results to be submitted for presentation at upcoming medical meeting – Seagen Inc. (NASDAQ:SGEN) and Astellas Pharma Inc. (TSE:4503) today announced positive topline results from the Phase 3 EV-302 clinical
3y agoALPMY SGEN TYO:4503PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 TrialPR Newswire– Trial results to be submitted for presentation at upcoming medical meeting – TOKYO and BOTHELL, Wash., Sept. 22, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura,
3y agoAMGN PFE SGENThe FTC cleared Amgen's $27.8 billion Horizon buyout — here's what it means for other massive pharma dealsCNBCSome analysts and M&A experts say the settlement agreement doesn't mean that the FTC will stop baring its teeth at other large buyouts in the industry.
3y agoGMAB SGENSeagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy AloneBusiness WireSeagen Inc. (NASDAQ:SGEN) and Genmab A/S (NASDAQ:GMAB) announced today that the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line
3y agoGMAB SGENGenmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to ChemotherapyBusiness WireCompany Announcement Phase 3 innovaTV 301 confirmatory trial met its primary endpoint of improved overall survival (OS) at predetermined, independent interim analysis Trial results to be submitted for presentation
3y agoSGENGenmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to ChemotherapyGlobeNewswireCompany Announcement Phase 3 innovaTV 301 confirmatory trial met its primary endpoint of improved overall survival (OS) at predetermined, independent interim analysisTrial results to be submitted for presentation at a
3y agoSGENSeagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast CancerBusiness WireSeagen Inc. (NASDAQ:SGEN) today announced that the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla®) met its
3y agoSGENSeagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance Driving Record Product Sales with Strong Growth and MomentumBusiness Wire-Record Net Product Sales of $544 Million in 2Q23, an Increase of 26% Over 2Q22, Contributing to Total Revenues of $604 Million in 2Q23- -Strong PADCEV® Growth Driven By Combination First-Line Advanced Urothelial
3y agoSGENSeagen to Report Second Quarter 2023 Financial Results on August 2, 2023Business WireSeagen Inc. (NASDAQ:SGEN) today announced that it will report its second quarter 2023 financial results on Wednesday, August 2, 2023. Given the previously announced agreement to be acquired by Pfizer Inc., Seagen will
3y agoSGENPhase 3 Trial of ADCETRIS® (brentuximab vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin LymphomaBusiness Wire– Results are from 1,500 patient trial conducted by German Hodgkin Study Group to test ADCETRIS regimen versus international standard eBEACOPP therapy – ADCETRIS regimen showed less peripheral neuropathy Seagen Inc.
3y agoSGENSix-Year Overall Survival Results Added to U.S. Prescribing Information for ADCETRIS® (brentuximab vedotin) as First-Line Treatment for Advanced Hodgkin LymphomaBusiness Wire– Update based on statistically significant 41% reduction in risk of death vs. previous standard of care in patients with frontline advanced classical Hodgkin lymphoma – – First and only targeted therapy inclusive
3y agoSGENSeagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)Business Wire– Updated phase 2 data results presented for ADCETRIS in combination with immune therapy nivolumab and doxorubicin and dacarbazine chemotherapy – – Regimen well-tolerated with fewer than half of patients developing
3y agoSGENSeagen Stockholders Approve Acquisition by PfizerBusiness WireFollowing a special meeting of its stockholders, Seagen Inc. (NASDAQ:SGEN) today announced that its stockholders voted to approve a proposal to adopt the previously announced merger agreement under which Pfizer will
3y agoPFE SGEN CVS AAPL+9Pfizer to raise $31 billion in debt offering to fund Seagen acquisition, SEC filing showsCNBCThe debt offering by Pfizer to buy cancer drug maker Seagen comes as Apple, Merck and T-Mobile tap the U.S. bond market ahead of the debt ceiling standoff.
3y agoHZNP RH HD COF+11Stocks making the biggest moves midday: Horizon Therapeutics, Capital One, RH, Home Depot and moreCNBCThese are the stocks posting the largest moves midday.
3y agoSE NUN-MX DISH HD+4Stocks making the biggest moves premarket: Home Depot, Capital One, Dish Network & moreCNBCThese are the stocks posting the largest moves in premarket trading.
3y agoALC FBRX INCY JAZZ+3MindMed Sends Letter to Shareholders Highlighting Company's Positive Momentum and Value-Enhancing StrategyBusiness WireFiles Definitive Proxy Materials in Connection with June 15, 2023 Annual Meeting Board's Nominees Possess Essential Pharmaceutical Industry, Capital Allocation and Corporate Governance Experience Needed to Drive
3y agoSGENSeagen Reports First Quarter 2023 Financial ResultsBusiness Wire-Total Revenues of $520 Million in 1Q23, Including Net Product Sales of $469 Million- -PADCEV® Granted FDA Accelerated Approval in Combination with KEYTRUDA® as First-Line Treatment for Cisplatin-Ineligible
3y agoSGENSeagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual MeetingBusiness Wire- Long-term follow-up data for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) in advanced bladder cancer to be featured as oral presentation – - Updated Phase 1 data on first-in-class
3y agoMNTV SGEN TA UNVRMoore Kuehn Encourages SGEN, TA, MNTV, and UNVR Investors to Contact Law FirmGlobeNewswireNEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
3y agoBMY FBRX INCY MNMD+1MindMed Files Preliminary Proxy Statement for 2023 Annual MeetingBusiness WirePresents Highly Qualified Slate of Director Nominees, Including Five Incumbent Board Members and New Independent Candidate David W. Gryska Highlights Significant Positive Momentum to Advance R&D Pipeline and
3y ago.NDX SHY ILMN AEP+1The lower inflation trade: History shows these stocks could win from the latest CPI reportCNBCCNBC Pro screened for Nasdaq-100 stocks that are correlated to the iShares 1-3 Year Treasury Bond ETF (SHY).
3y agoSGENSeagen to Report First Quarter 2023 Financial Results on April 27, 2023Business WireSeagen Inc. (NASDAQ:SGEN) today announced that it will report its first quarter 2023 financial results on Thursday, April 27, 2023. Given the recently announced agreement to be acquired by Pfizer Inc., Seagen will not
3y agoALPMY SGEN TYO:4503FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial CancerPR Newswire– First treatment option combining an antibody-drug conjugate plus a PD-1 inhibitor in this patient population – TOKYO and BOTHELL, Wash., April 3, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: